|
2026-05-19 |
2026-05-18 |
V
Vente
|
SVP, Finance
Dirigeant
|
84 464
+26.3%
153,17
3 405 821 $US
|
84 464
+26.3%
|
153,17
|
3 405 821 $US
|
|
|
2026-05-19 |
2026-05-18 |
V
Vente
|
Chief Medical Officer
Dirigeant
|
54 722
+11.2%
205,35
4 538 410 $US
|
54 722
+11.2%
|
205,35
|
4 538 410 $US
|
|
|
2026-05-19 |
2026-05-18 |
V
Vente
|
Chief Executive Officer
Administrateur exécutif
|
94 110
+30.7%
492,67
3 684 561 $US
|
94 110
+30.7%
|
492,67
|
3 684 561 $US
|
|
|
2026-02-26 |
2026-02-25 |
V
Vente
|
Actionnaire important
|
1 862 545
-100.0%
0,56
1 047 495 $US
|
1 862 545
-100.0%
|
0,56
|
1 047 495 $US
|
|
|
2026-02-26 |
2026-02-25 |
V
Vente
|
Actionnaire important
|
1 649 281
-100.0%
0,56
927 556 $US
|
1 649 281
-100.0%
|
0,56
|
927 556 $US
|
|
|
2026-02-25 |
2026-02-25 |
PrS
Vente proposée
|
10% Stockholder
Actionnaire important
|
939 273
0,60
565 442 $US
|
939 273
|
0,60
|
565 442 $US
|
|
|
2026-02-25 |
2026-02-25 |
PrS
Vente proposée
|
10% Stockholder
Actionnaire important
|
1 060 727
0,56
596 553 $US
|
1 060 727
|
0,56
|
596 553 $US
|
|
|
2026-02-26 |
2026-02-24 |
V
Vente
|
Actionnaire important
|
349 212
-15.8%
0,62
214 870 $US
|
349 212
-15.8%
|
0,62
|
214 870 $US
|
|
|
2026-02-26 |
2026-02-24 |
V
Vente
|
Actionnaire important
|
309 228
-15.8%
0,62
190 268 $US
|
309 228
-15.8%
|
0,62
|
190 268 $US
|
|
|
2026-02-24 |
2026-02-23 |
V
Vente
|
Actionnaire important
|
162 291
-6.8%
0,60
96 920 $US
|
162 291
-6.8%
|
0,60
|
96 920 $US
|
|
|
2026-02-24 |
2026-02-23 |
V
Vente
|
Actionnaire important
|
143 709
-6.8%
0,60
85 823 $US
|
143 709
-6.8%
|
0,60
|
85 823 $US
|
|
|
2026-02-24 |
2026-02-20 |
V
Vente
|
Actionnaire important
|
277 769
-10.5%
0,61
170 800 $US
|
277 769
-10.5%
|
0,61
|
170 800 $US
|
|
|
2026-02-24 |
2026-02-20 |
V
Vente
|
Actionnaire important
|
245 965
-10.5%
0,61
151 244 $US
|
245 965
-10.5%
|
0,61
|
151 244 $US
|
|
|
2026-02-20 |
2026-02-20 |
PrS
Vente proposée
|
10% Stockholder
Actionnaire important
|
1 408 910
0,62
872 538 $US
|
1 408 910
|
0,62
|
872 538 $US
|
|
|
2026-02-20 |
2026-02-20 |
PrS
Vente proposée
|
10% Stockholder
Actionnaire important
|
1 591 090
0,62
985 362 $US
|
1 591 090
|
0,62
|
985 362 $US
|
|
|
2026-02-17 |
2026-02-17 |
V
Vente
|
SVP, Finance
Dirigeant
|
2 022
-1.7%
0,64
1 300 $US
|
2 022
-1.7%
|
0,64
|
1 300 $US
|
|
|
2026-02-17 |
2026-02-17 |
V
Vente
|
SVP, Finance
Dirigeant
|
836
-0.7%
0,64
538 $US
|
836
-0.7%
|
0,64
|
538 $US
|
|
|
2026-02-17 |
2026-02-17 |
V
Vente
|
SVP, Finance
Dirigeant
|
611
-0.5%
0,64
393 $US
|
611
-0.5%
|
0,64
|
393 $US
|
|
|
2026-02-17 |
2026-02-17 |
V
Vente
|
Chief Medical Officer
Dirigeant
|
1 876
-0.9%
0,64
1 206 $US
|
1 876
-0.9%
|
0,64
|
1 206 $US
|
|
|
2026-02-17 |
2026-02-17 |
V
Vente
|
Chief Medical Officer
Dirigeant
|
1 642
-0.7%
0,64
1 056 $US
|
1 642
-0.7%
|
0,64
|
1 056 $US
|
|
|
2026-02-17 |
2026-02-17 |
PlS
Vente planifiée
|
Chief Medical Officer
Dirigeant
|
1 642
-0.7%
0,64
1 056 $US
|
1 642
-0.7%
|
0,64
|
1 056 $US
|
|
|
2026-02-17 |
2026-02-17 |
V
Vente
|
Chief Executive Officer
Administrateur exécutif
|
5 032
-1.1%
0,64
3 236 $US
|
5 032
-1.1%
|
0,64
|
3 236 $US
|
|
|
2026-02-17 |
2026-02-17 |
V
Vente
|
Chief Executive Officer
Administrateur exécutif
|
3 979
-0.9%
0,64
2 559 $US
|
3 979
-0.9%
|
0,64
|
2 559 $US
|
|
|
2026-02-17 |
2026-02-17 |
V
Vente
|
Chief Executive Officer
Administrateur exécutif
|
5 851
-1.3%
0,64
3 762 $US
|
5 851
-1.3%
|
0,64
|
3 762 $US
|
|
|
2026-02-17 |
2026-02-17 |
PrS
Vente proposée
|
Officer; Director
Administrateur exécutif
|
14 862
0,64
9 557 $US
|
14 862
|
0,64
|
9 557 $US
|
|
|
2026-02-17 |
2026-02-17 |
PrS
Vente proposée
|
Officer
Dirigeant
|
5 160
0,64
3 319 $US
|
5 160
|
0,64
|
3 319 $US
|
|
|
2026-02-12 |
2026-02-11 |
V
Vente
|
Actionnaire important
|
2 151 458
-44.8%
0,68
1 464 713 $US
|
2 151 458
-44.8%
|
0,68
|
1 464 713 $US
|
|
|
2026-02-12 |
2026-02-11 |
V
Vente
|
Actionnaire important
|
1 905 115
-44.8%
0,68
1 297 002 $US
|
1 905 115
-44.8%
|
0,68
|
1 297 002 $US
|
|
|
2026-02-11 |
2026-02-11 |
PrS
Vente proposée
|
10% Stockholder
Actionnaire important
|
657 627
0,68
446 989 $US
|
657 627
|
0,68
|
446 989 $US
|
|
|
2026-02-11 |
2026-02-11 |
PrS
Vente proposée
|
10% Stockholder
Actionnaire important
|
742 663
0,68
504 788 $US
|
742 663
|
0,68
|
504 788 $US
|
|
|
2026-02-12 |
2026-02-10 |
V
Vente
|
Actionnaire important
|
182 295
-3.7%
0,82
148 771 $US
|
182 295
-3.7%
|
0,82
|
148 771 $US
|
|
|
2026-02-12 |
2026-02-10 |
V
Vente
|
Actionnaire important
|
161 422
-3.7%
0,82
131 736 $US
|
161 422
-3.7%
|
0,82
|
131 736 $US
|
|
|
2026-02-10 |
2026-02-10 |
PrS
Vente proposée
|
10% Stockholder
Actionnaire important
|
1 591 090
0,79
1 256 961 $US
|
1 591 090
|
0,79
|
1 256 961 $US
|
|
|
2026-02-10 |
2026-02-10 |
PrS
Vente proposée
|
10% Stockholder
Actionnaire important
|
1 408 910
0,79
1 113 038 $US
|
1 408 910
|
0,79
|
1 113 038 $US
|
|
|
2025-11-17 |
2025-11-17 |
V
Vente
|
Chief Executive Officer
Administrateur exécutif
|
3 126
-1.0%
1,33
4 158 $US
|
3 126
-1.0%
|
1,33
|
4 158 $US
|
|
|
2025-11-17 |
2025-11-17 |
V
Vente
|
SVP, Finance
Dirigeant
|
1 367
-1.4%
1,33
1 818 $US
|
1 367
-1.4%
|
1,33
|
1 818 $US
|
|
|
2025-11-17 |
2025-11-17 |
V
Vente
|
Chief Medical Officer
Dirigeant
|
2 877
-1.7%
1,33
3 826 $US
|
2 877
-1.7%
|
1,33
|
3 826 $US
|
|
|
2025-08-18 |
2025-08-18 |
PrS
Vente proposée
|
Officer
Dirigeant
|
5 053
1,25
6 331 $US
|
5 053
|
1,25
|
6 331 $US
|
|
|
2025-08-18 |
2025-08-18 |
PrS
Vente proposée
|
Officer; Director
Administrateur exécutif
|
14 533
1,25
18 210 $US
|
14 533
|
1,25
|
18 210 $US
|
|
|
2025-08-18 |
2025-08-18 |
V
Vente
|
SVP, Finance
Dirigeant
|
1 722
-1.8%
1,25
2 158 $US
|
1 722
-1.8%
|
1,25
|
2 158 $US
|
|
|
2025-08-18 |
2025-08-18 |
V
Vente
|
SVP, Finance
Dirigeant
|
717
-0.7%
1,25
898 $US
|
717
-0.7%
|
1,25
|
898 $US
|
|
|
2025-08-18 |
2025-08-18 |
V
Vente
|
SVP, Finance
Dirigeant
|
523
-0.5%
1,25
655 $US
|
523
-0.5%
|
1,25
|
655 $US
|
|
|
2025-08-18 |
2025-08-18 |
V
Vente
|
Chief Medical Officer
Dirigeant
|
1 837
-1.1%
1,25
2 302 $US
|
1 837
-1.1%
|
1,25
|
2 302 $US
|
|
|
2025-08-18 |
2025-08-18 |
V
Vente
|
Chief Medical Officer
Dirigeant
|
1 608
-0.9%
1,25
2 015 $US
|
1 608
-0.9%
|
1,25
|
2 015 $US
|
|
|
2025-08-18 |
2025-08-18 |
PlS
Vente planifiée
|
Chief Medical Officer
Dirigeant
|
1 608
-0.9%
1,25
2 015 $US
|
1 608
-0.9%
|
1,25
|
2 015 $US
|
|
|
2025-08-18 |
2025-08-18 |
V
Vente
|
Chief Executive Officer
Administrateur exécutif
|
4 920
-1.6%
1,25
6 165 $US
|
4 920
-1.6%
|
1,25
|
6 165 $US
|
|
|
2025-08-18 |
2025-08-18 |
V
Vente
|
Chief Executive Officer
Administrateur exécutif
|
3 893
-1.2%
1,25
4 878 $US
|
3 893
-1.2%
|
1,25
|
4 878 $US
|
|
|
2025-08-18 |
2025-08-18 |
V
Vente
|
Chief Executive Officer
Administrateur exécutif
|
5 720
-1.8%
1,25
7 167 $US
|
5 720
-1.8%
|
1,25
|
7 167 $US
|
|
|
2025-05-16 |
2025-05-16 |
V
Vente
|
Chief Medical Officer
Dirigeant
|
2 937
-1.7%
0,44
1 300 $US
|
2 937
-1.7%
|
0,44
|
1 300 $US
|
|
|
2025-05-16 |
2025-05-16 |
V
Vente
|
Chief Executive Officer
Administrateur exécutif
|
3 189
-1.0%
0,44
1 412 $US
|
3 189
-1.0%
|
0,44
|
1 412 $US
|
|
|
2025-05-16 |
2025-05-16 |
V
Vente
|
SVP, Finance
Dirigeant
|
1 390
-1.4%
0,44
615 $US
|
1 390
-1.4%
|
0,44
|
615 $US
|
|
|
2025-03-10 |
2025-03-10 |
PrS
Vente proposée
|
Officer
Dirigeant
|
7 398
0,54
3 983 $US
|
7 398
|
0,54
|
3 983 $US
|
|
|
2025-03-10 |
2025-03-10 |
PrS
Vente proposée
|
Officer; Director
Administrateur exécutif
|
9 741
0,54
5 245 $US
|
9 741
|
0,54
|
5 245 $US
|
|
|
2025-03-10 |
2025-03-10 |
V
Vente
|
SVP, Finance
Dirigeant
|
845
-0.8%
0,54
455 $US
|
845
-0.8%
|
0,54
|
455 $US
|
|
|
2025-03-10 |
2025-03-10 |
V
Vente
|
SVP, Finance
Dirigeant
|
620
-0.6%
0,54
334 $US
|
620
-0.6%
|
0,54
|
334 $US
|
|
|
2025-03-10 |
2025-03-10 |
V
Vente
|
SVP, Finance
Dirigeant
|
1 017
-1.0%
0,54
548 $US
|
1 017
-1.0%
|
0,54
|
548 $US
|
|
|
2025-03-10 |
2025-03-10 |
V
Vente
|
Chief Executive Officer
Administrateur exécutif
|
3 947
-1.2%
0,54
2 125 $US
|
3 947
-1.2%
|
0,54
|
2 125 $US
|
|
|
2025-03-10 |
2025-03-10 |
V
Vente
|
Chief Executive Officer
Administrateur exécutif
|
5 794
-1.8%
0,54
3 119 $US
|
5 794
-1.8%
|
0,54
|
3 119 $US
|
|
|
2025-03-10 |
2025-03-10 |
V
Vente
|
Chief Medical Officer
Dirigeant
|
1 598
-0.9%
0,54
860 $US
|
1 598
-0.9%
|
0,54
|
860 $US
|
|
|
2025-03-10 |
2025-03-10 |
V
Vente
|
Chief Medical Officer
Dirigeant
|
4 073
-2.3%
0,54
2 193 $US
|
4 073
-2.3%
|
0,54
|
2 193 $US
|
|
|
2025-03-10 |
2025-03-10 |
PlS
Vente planifiée
|
Chief Medical Officer
Dirigeant
|
1 727
-0.9%
0,54
930 $US
|
1 727
-0.9%
|
0,54
|
930 $US
|
|
|
2025-03-07 |
2025-03-05 |
A
Achat
|
Actionnaire important
|
35 714 284
+262.6%
0,70
24 999 999 $US
|
35 714 284
+262.6%
|
0,70
|
24 999 999 $US
|
|
|
2025-03-07 |
2025-03-05 |
A
Achat
|
Administrateur non-exécutif
Actionnaire important
|
35 714 284
+262.6%
0,70
24 999 999 $US
|
35 714 284
+262.6%
|
0,70
|
24 999 999 $US
|
|
|
2024-11-18 |
2024-11-18 |
V
Vente
|
SVP, Accounting and Fin. Ops.
Dirigeant
|
2 258
-3.6%
2,12
4 787 $US
|
2 258
-3.6%
|
2,12
|
4 787 $US
|
|
|
2024-08-19 |
2024-08-16 |
V
Vente
|
SVP, Accounting and Fin. Ops.
Dirigeant
|
807
-1.3%
2,89
2 336 $US
|
807
-1.3%
|
2,89
|
2 336 $US
|
|
|
2024-08-19 |
2024-08-16 |
V
Vente
|
SVP, Accounting and Fin. Ops.
Dirigeant
|
654
-1.0%
2,89
1 893 $US
|
654
-1.0%
|
2,89
|
1 893 $US
|
|
|
2024-08-19 |
2024-08-16 |
V
Vente
|
SVP, Accounting and Fin. Ops.
Dirigeant
|
902
-1.4%
2,89
2 611 $US
|
902
-1.4%
|
2,89
|
2 611 $US
|
|
|
2024-08-16 |
2024-08-16 |
PrS
Vente proposée
|
Officer
Dirigeant
|
7 428
2,89
21 467 $US
|
7 428
|
2,89
|
21 467 $US
|
|
|
2024-08-16 |
2024-08-16 |
PrS
Vente proposée
|
Officer; Director
Administrateur exécutif
|
9 748
2,89
28 172 $US
|
9 748
|
2,89
|
28 172 $US
|
|
|
2024-08-16 |
2024-08-16 |
PlS
Vente planifiée
|
Chief Medical Officer
Dirigeant
|
1 625
-1.5%
2,89
4 704 $US
|
1 625
-1.5%
|
2,89
|
4 704 $US
|
|
|
2024-08-16 |
2024-08-16 |
PlS
Vente planifiée
|
Chief Medical Officer
Dirigeant
|
5 803
-5.1%
2,89
16 797 $US
|
5 803
-5.1%
|
2,89
|
16 797 $US
|
|
|
2024-08-16 |
2024-08-16 |
V
Vente
|
Chief Executive Officer
Administrateur exécutif
|
3 946
-2.1%
2,89
11 422 $US
|
3 946
-2.1%
|
2,89
|
11 422 $US
|
|
|
2024-08-16 |
2024-08-16 |
V
Vente
|
Chief Executive Officer
Administrateur exécutif
|
5 802
-2.9%
2,89
16 794 $US
|
5 802
-2.9%
|
2,89
|
16 794 $US
|
|
|
2024-03-06 |
2024-03-05 |
PlS
Vente planifiée
|
Chief Scientific Officer
Dirigeant
|
3 300
-1.3%
7,00
23 101 $US
|
3 300
-1.3%
|
7,00
|
23 101 $US
|
|
|
2024-03-05 |
2024-03-05 |
PrS
Vente proposée
|
Officer
Dirigeant
|
20 000
6,61
132 200 $US
|
20 000
|
6,61
|
132 200 $US
|
|